Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR-T Cells for NY-ESO-1+ Solid Tumors
NCT05648994Phase 1Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Dec 2022
- Primary completion
- Feb 2024
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of letetresgene autoleucel in solid tumor, sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Event at 24 months. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
letetresgene autoleucel
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05648994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05648994.